Management of posterior reversible encephalopathy syndrome induced by carfilzomib in a patient with multiple myeloma

Journal of Clinical Oncology

Volumn 34, Issue 2, 2016, Pages e1-e5

  Cai, Xuemei ^a   Bhattacharyya, Shamik ^a   Plitt, Anna ^a   Raibagkar, Pooja ^a   LaBuzetta, Jamie N ^a   Schleicher, Stephen M ^a   Munshi, Nikhil C ^b   Klein, Joshua P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENCE JONES PROTEIN; BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; LABETALOL; LENALIDOMIDE; LORAZEPAM; MELPHALAN; NIMODIPINE; THALIDOMIDE; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; ETIRACETAM; IMMUNOGLOBULIN KAPPA CHAIN; NOOTROPIC AGENT; OLIGOPEPTIDE; PIRACETAM; TUMOR MARKER;

ADULT; APRAXIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLURRED VISION; BRAIN EDEMA; CASE REPORT; DISEASE COURSE; DISORIENTATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; KIDNEY FAILURE; MIDDLE AGED; MULTIPLE MYELOMA; NEUROIMAGING; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROTEINURIA; SEIZURE; ANALOGS AND DERIVATIVES; BLOOD; BRAIN; CHEMICALLY INDUCED; COMPLICATION; DISEASE MANAGEMENT; DRUG EFFECTS; IMMUNOLOGY; NEUROLOGIC EXAMINATION; PATHOLOGY; PATHOPHYSIOLOGY; POLYNEUROPATHIES; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; PROCEDURES; SECONDARY PREVENTION; SEIZURES;

ANTICONVULSANTS; ANTIHYPERTENSIVE AGENTS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BORTEZOMIB; BRAIN; DISEASE MANAGEMENT; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MULTIPLE MYELOMA; NEUROLOGIC EXAMINATION; NIMODIPINE; NOOTROPIC AGENTS; OLIGOPEPTIDES; PIRACETAM; POLYNEUROPATHIES; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; SECONDARY PREVENTION; SEIZURES;

EID: 84954202726     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.6166     Document Type: Article

References (17)

1. Kortuem KM, Stewart AK: Carfilzomib. Blood 121:893-897, 2013
2. Demo SD, Kirk CJ, Aujay MA, et al: Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 67:6383-6391, 2007
3. Richardson PG, Briemberg H, Jagannath S, et al: Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24:3113-3120, 2006
4. O'Connor OA, Stewart AK, Vallone M, et al: A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 15:7085-7091, 2009
5. Alsina M, Trudel S, Furman RR, et al: A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res 18:4830-4840, 2012
6. Siegel DS, Martin T, Wang M, et al: A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120:2817-2825, 2012
7. Fugate JE, Claassen DO, Cloft HJ, et al: Posterior reversible encephalopathy syndrome: Associated clinical and radiologic findings. Mayo Clin Proc 85:427-432, 2010
8. Bartynski WS: Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol 29:1036-1042, 2008
9. Stevens CJ, Heran MK: The many faces of posterior reversible encephalopathy syndrome. Br J Radiol 85:1566-1575, 2012
10. Vaughn C, Zhang L, Schiff D: Reversible posterior leukoencephalopathy syndrome in cancer. Curr Oncol Rep 10:86-91, 2008
11. Terwiel E, Hanrahan R, Lueck C, et al: Reversible posterior encephalopathy syndrome associated with bortezomib. Intern Med J 40:69-71, 2010
12. Oshikawa G, Kojima A, Doki N, et al: Bortezomib-induced posterior reversible encephalopathy syndrome in a patient with newly diagnosed multiple myeloma. Intern Med 52:111-114, 2013
13. Kager LM, Kersten MJ, Kloppenborg RP, et al: Reversible posterior leucoencephalopathy syndrome associated with bortezomib in a patient with relapsed multiple myeloma. BMJ Case Rep 2009, 2009
14. Kelly K, Kalachand R, Murphy P: Bortezomib-induced reversible posterior leucoencephalopathy syndrome. Br J Haematol 141:566, 2008
15. Kappers MH, van Esch JH, Sleijfer S, et al: Cardiovascular and renal toxicity during angiogenesis inhibition: Clinical and mechanistic aspects. J Hypertens 27:2297-2309, 2009
16. Glusker P, Recht L, Lane B: Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354:980-982, 2006
17. Zuber M, Touzé E, Domigo V, et al: Reversible cerebral angiopathy: Efficacy of nimodipine. J Neurol 253:1585-1588, 2006